Stocks · News reference
Elanco beat second-quarter estimates, raised 2026 guidance and cited strong Pet Health demand, Zenrelia growth and expanding margins.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Lawrence Erik Kurzius, Director at Elanco Animal Health, purchased 40,000 shares at $23.40 per share on August 20, 2026, expanding his direct holdings by 27%. The insider purchase signals confidence in the company, with analysts showing strong bullish sentiment—89% of 18 analysts rate it a buy with a median 12-month price target of $32, representing potential 31% upside.
The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipelineINDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ -- Elanco Animal
Bryn Talkington picked Horizon Kinetics, Stephanie Link chose Elanco Animal Health, and Jason Snipe recommended Netflix.